FibroGen, Inc (NASDAQ:FGEN) has earned an average recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $66.60.

FGEN has been the subject of a number of recent analyst reports. Stifel Nicolaus reiterated a “buy” rating and issued a $80.00 price target on shares of FibroGen in a research report on Thursday, September 14th. Jefferies Group LLC restated a “buy” rating and set a $75.00 target price on shares of FibroGen in a research note on Tuesday, September 12th. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) lowered FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price target for the company. in a research note on Friday, July 21st. Finally, BidaskClub cut FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st.

In related news, CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $53.46, for a total transaction of $2,065,480.56. Following the sale, the chief executive officer now owns 3,246,754 shares of the company’s stock, valued at $173,571,468.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Pat Cotroneo sold 95,000 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the sale, the vice president now directly owns 173,366 shares in the company, valued at approximately $8,774,053.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 506,828 shares of company stock worth $22,574,671. Corporate insiders own 14.90% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. purchased a new position in shares of FibroGen in the 1st quarter worth $111,000. Quantbot Technologies LP bought a new stake in shares of FibroGen in the 2nd quarter worth about $128,000. SG Americas Securities LLC increased its holdings in shares of FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 412 shares during the last quarter. Amalgamated Bank bought a new stake in shares of FibroGen in the 2nd quarter worth about $237,000. Finally, BNP Paribas Arbitrage SA increased its holdings in shares of FibroGen by 589.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 6,327 shares during the last quarter. Institutional investors and hedge funds own 47.49% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “FibroGen, Inc (FGEN) Receives Average Rating of “Buy” from Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/10/04/fibrogen-inc-fgen-receives-average-rating-of-buy-from-brokerages.html.

FibroGen (NASDAQ FGEN) opened at 56.05 on Wednesday. The company’s 50-day moving average is $48.38 and its 200 day moving average is $34.57. FibroGen has a 52 week low of $15.60 and a 52 week high of $56.15. The stock’s market cap is $3.99 billion.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). The company had revenue of $29.00 million for the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. On average, analysts expect that FibroGen will post ($1.80) earnings per share for the current fiscal year.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.